帕立骨化醇与骨化三醇对CKD肾纤维化作用的实验研究
该研究在7/8肾切除慢性肾衰竭模型中,比较等效剂量(3/1剂量比)的帕立骨化醇与骨化三醇治疗4周的抗纤维化效果。结果显示帕立骨化醇通过抑制RAAS激活、肾脏炎症及上皮/间质转化,有效减轻肾间质纤维化;骨化三醇在多数生物标志物上呈相似趋势但无显著变化。
要点
- 帕立骨化醇可减轻CRF模型中的肾间质纤维化。
- 其机制涉及抑制RAAS、炎症及上皮/间质转化。
- 等效剂量下骨化三醇对多数标志物无显著改变。
核心结论
- 帕立骨化醇通过抑制RAAS、炎症和上皮/间质转化的综合作用,有效减轻CRF诱导的肾间质纤维化。
研究设计与样本
- 采用7/8肾切除实验性慢性肾衰竭模型,比较等效剂量(帕立骨化醇/骨化三醇=3/1)治疗4周的抗纤维化效果。
主要发现
- CRF增加RAAS激活、肾脏炎症和间质纤维化。
- 帕立骨化醇降低肾脏胶原I和肾间质纤维化,通过改变肾脏renin、ATR1和ATR2 mRNA水平降低RAAS激活,并通过减少肾脏炎症白细胞(CD45)、ADAM mRNA、TGF-β mRNA和蛋白、维持E-cadherin mRNA水平减轻炎症。
- 骨化三醇在多数上述生物标志物上呈相似趋势但无显著变化。
临床怎么用
- 在CKD实验模型中,帕立骨化醇可能通过多靶点抑制纤维化,但临床转化需进一步验证。
局限性
- 研究为动物实验(7/8肾切除模型),结果不能直接外推至临床CKD患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In chronic kidney disease, the activation of the renin-angiotensin-aldosterone system (RAAS) and renal inflammation stimulates renal fibrosis and the progression to end-stage renal disease. The low levels of vitamin D receptor (VDR) and its activators (VDRAs) contribute to worsen secondary hyperparathyroidism and renal fibrosis. METHODS: The 7/8 nephrectomy model of experimental chronic renal failure (CRF) was used to examine the anti-fibrotic effects of treatment with two VDRAs, paricalcitol and calcitriol, at equivalent doses (3/1 dose ratio) during 4 weeks. RESULTS: CRF increased the activation of the RAAS, renal inflammation and interstitial fibrosis. Paricalcitol treatment reduced renal collagen I and renal interstitial fibrosis by decreasing the activation of the RAAS through renal changes in renin, angiotensin receptor 1 (ATR1) and ATR2 mRNAs levels and renal inflammation by decreasing renal inflammatory leucocytes (CD45), a desintegrin and metaloproteinase mRNA, transforming growth factor beta mRNA and protein, and maintaining E-cadherin mRNA levels. Calcitriol showed similar trends without significant changes in most of these biomarkers. CONCLUSIONS: Paricalcitol effectively attenuated the renal interstitial fibrosis induced by CRF through a combination of inhibitory actions on the RAAS, inflammation and epithelial/mesenchymal transition.
引用
- Martínez-Arias L, Panizo S, Alonso-Montes C, et al. Effects of calcitriol and paricalcitol on renal fibrosis in CKD. Nephrol Dial Transplant. 2021. PMID: 33416889. doi:10.1093/ndt/gfaa373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。